[14] The latter is particularly relevant, since bladder cancer is the second most prevalent malignancy after prostate cancer in middle-aged and elderly men ... patients with advanced TCC and ...

Every so often there is an urgent call for a national prostate cancer screening program to be introduced, usually following ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

Initial Keytruda showed consistent antitumor activity and safety in patients with advanced bladder cancer ineligible for ...

Discover real-world data showing that only a minority of patients complete the recommended 4–6 chemotherapy cycles in bladder ...

The following is a summary of “Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds. Surgery for prostate cancers increases a man's risk of urinary ...

Prostate cancer is a malignant tumor that develops in the prostate gland, a part of the male reproductive system.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...